Search

Here, a covalent inhibitor targeting cyclin-dependent kinase 7 (CDK7) demonstrates in vitro and in vivo efficacy against T-cell acute lymphoblastic leukaemia by downregulating oncogenic transcriptional programs.

Jänne and colleagues discover and characterize an allosteric EGFR inhibitor with efficacy against therapy-resistant mutations and show preclinical efficacy as monotherapy and in combination in patient-derived xenograft models.

Two degraders targeting zinc finger transcription factor IKZF2 (Helios) were developed by reprogramming CRL4^CRBN E3 ligase, and the pharmacologic degradation of Helios results in T_reg destabilization.

The discovery of a specific CDK12 bivalent degrader, BSJ-4-116, reveals that chronic exposure of MOLT-4 and Jurkat cells to BSJ-4-116 leads to acquired resistance to the compound via point mutations in the CDK12 kinase domain.

The dTAG system is used to rapidly deplete tagged target proteins in vitro and in vivo, but there are context- and protein-specific differences in its effectiveness. Here, the authors develop a second generation dTAG molecule that can degrade previously recalcitrant target proteins in cells and mice.

A highly selective inhibitor of the DCLK1/2 kinases is used to uncover the consequences of DCLK1 inhibition on viability, phosphosignaling and the transcriptome in patient-derived organoid models of pancreatic ductal adenocarcinoma.

A highly selective covalent peptide inhibitor of the peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1) is used to show that Pin1 cooperates with mutant KRAS to promote pancreatic ductal adenocarcinoma (PDAC) transformation.

GNF-2 is a recently discovered, selective allosteric Bcr–Abl inhibitor. Solution NMR, X-ray crystallography, mutagenesis and hydrogen exchange mass spectrometry are now used to show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site. The results show that the combination of allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.

A small molecule inhibits CDK12 and CDK13 activity through covalent modification of Cys residues and reveals a role of the two kinases in regulating Pol II processivity and super-enhancer-driven transcription factor and DNA damage response gene expression.

A selective small-molecule degrader of CDK9 was generated by conjugating an imide to SNS-032, a promiscuous ATP-site-directed CDK binder. The pharmacological consequences of CDK9 degradation versus inhibition were compared.

Selective TRIM24 degradation is achieved by co-opting the VHL E3 ubiquitin ligase machinery. TRIM24 degradation outperforms bromodomain inhibition, with an enhanced antiproliferative effect in acute leukemia, a novel context of TRIM24 dependency.

The dTAG system pairs potent heterobifunctional degraders and extensible tagging strategies to achieve immediate and reversible degradation of divergent proteins, facilitating biological investigation and drug target validation in cells and in mice.

Inhibitors of CDK8 enhance IL-10 production during innate immune activation in human and mouse primary macrophages and dendritic cells via diminished phosphorylation of the c-Jun subunit of the AP-1 transcription regulatory complex.

The use of ATP competitive kinase inhibitors against the pseudokinase Her3 has been largely unsuccessful. Hydrophobic tagging of a covalent kinase inhibitor promotes Her3 degradation and prevents productive dimerization and signaling.

Non-small-cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) often show a clinical response to EGFR kinase inhibitors but tend to develop drug-resistance mutations, including the gatekeeper T790M mutation. Here, a new class of EGFR inhibitors is developed; these agents are 30- to 100-fold more potent against EGFR with the T790M mutation, and up to 100-fold less potent against wild-type EGFR, than current EGFR inhibitors.

A potent and selective inhibitor of the kinase LRRK2 identified using an in vitro ATP-site competition binding assay also inhibits the G2019S mutant, implicated in Parkinson's disease, as well as the regulatory feedback loop where LRRK2 is phosphorylated and binds 14-3-3 protein.

Inhibition of kinase activity has received enormous interest as a therapeutic strategy for cancer. This Review discusses the current approaches to develop and characterize new inhibitors.

mTORC1 is shown to regulate a translational program that requires the rapamycin-resistant 4E-BP family of translational repressors and consists almost entirely of mRNAs containing 5′ terminal oligopyrimidine or related motifs.

Existing kinase inhibitor drugs predominantly target receptor tyrosine kinases in cancer. Here, Gray and Ferguson review novel kinase targets in oncology, degenerative diseases, inflammatory disorders and infectious diseases. Advances in medicinal chemistry, selectivity profiling and computer-aided drug design, which are enabling the design of improved kinase inhibitors, are discussed.

Protein kinases have emerged as one of the most successful families of drug targets. To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes. Here we discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them.

Translational research in academia is extending beyond the traditional involvement in clinical trials to the early phases of the drug discovery process. Examples of successful academic-industrial partnerships illustrate the ways in which they can enable the discovery of new medicines.